Rubius Therapeutics Inc (fka RUBY)

[Frankestin]

https://www.rubiustx.com/about-us/#board-of-directors

Rubius has recently generated new non-human primate data with the next generation cell conjugation RED PLATFORM, demonstrating longer circulation time than observed with the first generation platform and pronounced pharmacodynamic effects as shown by increased levels of interferon gamma, a cytokine critical to both innate and adaptive immunity. In parallel, the Company has advanced a next generation Red Cell Therapeutic, RTX-250, an antigen-specific therapy that is designed to activate dendritic cells.

With the first generation Red Cell Therapeutics, Rubius demonstrated that engineered red blood cells could be manufactured at scale, safely administered and activate a patient’s immune system, resulting in clinical benefit in certain cancer patients, including evidence of tumor shrinkage and prolonged stable disease in PD-(L)-1 refractory solid tumors.

ISTITUTIONS Total (for Top 20) 24.30
FUNDS Total (for Top 20) 80.47

Institutional Shares (Long) 74,569,319 - 82.51% (ex 13D/G)
Insider Ownership 12,112,658 - 13.40%